Order Now, Ships Today
One-time
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
FOXO4-DRI is a synthetic research peptide designed as a D-retro-inverso (DRI) analog of a FOXO4 protein interaction motif. It functions as a peptide inhibitor of the interaction between FOXO4 and the tumor suppressor protein p53. Each vial of FOXO4-DRI 10mg contains 10 mg of lyophilized peptide intended exclusively for controlled laboratory research, particularly in senescence and cell-fate studies.
FOXO4-DRI is manufactured under controlled conditions and typically released at ≥98–99% purity, confirmed by HPLC and/or LC-MS. A lot-specific Certificate of Analysis generally includes: Identity confirmation of FOXO4-DRI (mass spectrometry and peptide mapping) Purity profile and chromatograms Peptide content (10 mg per vial) Appearance (white to off-white lyophilized powder) Residual solvent and moisture content within internal specifications The compound is supplied strictly for research use only and is not intended for human consumption or therapeutic use.
Products from Elite Miami Peptides do not include usage instructions, as they are strictly for in vitro research and prohibited by law for human or animal use. Misuse or unlawful application will result in permanent denial of service.
Each vial contains exactly what’s indicated on the label. For instance, a 10mg vial contains precisely 10mg of lyophilized peptide. Researchers may divide it into smaller research portions—such as four 2.5mg aliquots—but the total content remains the same.
Yes. All peptides are supplied in lyophilized powder form and do not come reconstituted. Any extra materials required for research, such as solvents or diluents, must be obtained separately.
When stored as a dry powder, peptides remain stable for up to 2 years.
Once reconstituted, the solution should be kept refrigerated and is typically stable for up to 2 months under proper storage conditions.
FOXO4-DRI is a D-retro-inverso peptide derived from a FOXO4 domain that binds p53 in senescent cells. By competitively disrupting FOXO4–p53 interaction, FOXO4-DRI has been shown in preclinical models to alter p53 nuclear retention in senescent cells, promoting p53-mediated apoptosis in those cells while sparing most non-senescent counterparts. This has made FOXO4-DRI a widely used tool compound in the field of cellular senescence, aging research and tissue homeostasis, enabling mechanistic studies on senolytic and senomorphic strategies.
In simple terms, FOXO4-DRI is a lab-only peptide designed to interfere with a key handshake between two proteins: FOXO4 and p53. That handshake is important for keeping certain “aged” or senescent cells alive. In experimental systems, blocking this interaction helps researchers explore what happens when some of these senescent cells are selectively pushed toward self-destruction, and how that affects tissue function, inflammation and aging markers. It is not a drug, supplement or anti-aging therapy and is supplied only for research use in controlled laboratory settings.
⚠️ Disclaimer: this product is not approved for medical use and is not intended to diagnose, treat, or prevent any disease. All information provided is for educational and research purposes only, and this product must never be used in humans or animals.
FOXO4-DRI emerged from work on transcription factor FOXO4 and its role in maintaining the viability of senescent cells. Researchers identified a short FOXO4–p53 interaction region and converted it into a D-retro-inverso peptide to improve stability and cell permeability. In landmark preclinical studies, FOXO4-DRI was used to probe whether selectively targeting senescent cells could improve tissue function and health-span indicators in animal models of aging and therapy-induced damage. Since then, it has been adopted as a reference senolytic tool in many senescence-related research programs.
FOXO4-DRI is a D-retro-inverso peptide, meaning it uses D-amino acids arranged in reverse order relative to the native FOXO4 sequence segment while preserving a similar three-dimensional orientation of the side chains. Key structural features include: Backbone: D-amino acid sequence corresponding to a FOXO4–p53 binding motif in reverse order Type: cell-penetrating, D-retro-inverso peptide inhibitor Form: lyophilized powder, typically supplied as a salt (e.g., acetate) to aid solubility This D-retro-inverso design improves resistance to proteolytic degradation and supports intracellular activity in vitro and in vivo research models.
In preclinical cellular models, FOXO4-DRI has been reported to: Disrupt FOXO4–p53 interaction and reduce nuclear co-localization in senescent cells Promote p53-dependent apoptosis preferentially in senescent, rather than proliferating, cells Decrease markers of cellular senescence (such as SA-β-gal positivity and selected SASP factors) in treated cultures In animal studies, administration of FOXO4-DRI has been associated with: Reduction of senescence markers in select tissues Improvements in certain functional readouts (such as aspects of physical performance or organ function) in aging or therapy-damaged models Modulation of inflammatory and tissue-remodeling profiles linked to senescent-cell burden These outcomes vary depending on model, dosing regimen, route and experimental design, and remain limited to exploratory preclinical work.
Put simply, scientists use FOXO4-DRI as a precision tool to test what happens when they selectively “target” senescent cells that rely on the FOXO4–p53 interaction to stay alive. Early lab and animal studies suggest it can reduce senescence markers and improve some functional measures in those models, but this is still early-stage research. The findings do not prove safety or effectiveness for treating aging or any disease in humans, and FOXO4-DRI should be handled solely as a research chemical under appropriate laboratory conditions.
– Preclinical studies describing FOXO4-DRI as a D-retro-inverso peptide that disrupts FOXO4–p53 interaction and targets senescent cells in vitro and in vivo. – Reviews on senolytics and the role of FOXO4–p53 signaling in cellular senescence and tissue homeostasis.
Our specialists respond within minutes to any order or product inquiry.
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
By clicking the button above, you agree to receive marketing text messages from Elite Miami Peptides at the number provided. Consent is not a condition of purchase. Msg & data rates may apply. Reply STOP to cancel, HELP for help. View our Privacy Policy.
All compounds from Elite Miami Peptides are intended strictly for laboratory research purposes.
They are not for human use, consumption, or therapeutic applications.
Products are supplied exclusively to qualified professionals working in compliance with all applicable laws and regulations.
